GGrantIndex
← Search

Early Phase Clinical Research Support

$120,255P30FY2016CANIH

University Of Arizona, Tucson AZ

Investigators

Linked publications, trials & patents

Paper 39631050Paper 39622842Paper 39612086Paper 39361227Paper 39312766Paper 39151774Paper 39100646Paper 39075233Paper 38875929Paper 38858600Paper 38826434Paper 38804255Paper 38769192Paper 38759377Paper 38729260Paper 38719743Paper 38715255Paper 38687603Paper 38658768Paper 38639990Paper 38613866Paper 38612480Paper 38474232Paper 38464045Paper 38453918Paper 38386696Paper 38386396Paper 38328594Paper 38313301Paper 38309054Paper 38291312Paper 38215755Paper 38203706Paper 38199366Paper 38164625Paper 38164604Paper 38097734Paper 38097593Paper 38096366Trial NCT07214506Trial NCT06009926Trial NCT05699603Trial NCT05237960Trial NCT05121051Trial NCT04530552Trial NCT03708055Trial NCT03602066Trial NCT03601507Trial NCT03578432Trial NCT03422536Trial NCT03402230Trial NCT03376971Trial NCT03365895Trial NCT03196180Trial NCT02581137Trial NCT02568566Trial NCT02348203Trial NCT02326805Trial NCT02123849Trial NCT01686165Trial NCT01433913Trial NCT01394211Trial NCT01385280Trial NCT01370889Trial NCT01288261Trial NCT01172028Trial NCT01097304Trial NCT01077453Trial NCT00980395Trial NCT00978718Trial NCT00900432Trial NCT00900341Trial NCT00898703Trial NCT00896935Trial NCT00892268Trial NCT00841204Trial NCT00752739Trial NCT00732498Trial NCT00721877Trial NCT00702299Trial NCT00701857Trial NCT00699907Trial NCT00619060Trial NCT00608634Trial NCT00601640Trial NCT00410618Trial NCT00373022Trial NCT00363805Trial NCT00303823Trial NCT00245024Trial NCT00091325Trial NCT00078897Trial NCT00003307Trial NCT00003082Patent 9486545Patent 9435812Patent 9415110Patent 9262824Patent 5650489Patent 5510240

Abstract

Project Summary / Abstract: Early Phase Clinical Research Support (EPCRS) The goal of the EPCRS Program is to provide critical support to the UACC Early Phase Program (EPP), in which Early Phase trials with the potential for high impact are developed and initiated to provide access to Early Phase research to patients and high-risk persons from the UACC catchment area. The EPP provides support for short-term Pilot (pre-Phase I) and Phase I clinical research studies originating from UACC investigators whose outcomes form the basis of an application for later phase studies through external competitive grants, national group, or industry-sponsored trial support. The Phase I Multi-Disciplinary Team (MDT) manages the overall portfolio of Early Phase research and constitutes the oversight committee that reviews Early Phase research concepts. High priority is given to innovative investigator-initiated trials that focus on initial Early Phase testing of a novel candidate agent, device, or biomarker for the detection, prevention, or treatment of cancer; priority is given to those trials for which the preclinical development of translational science was performed by UACC researchers. The Phase I MDT is comprised of physicians and scientists with expertise in cancer therapeutics and chemoprevention trial development and basic scientists who conduct translational laboratory-based research. Early Phase concepts are further triaged by the Clinical Research Oversight Council, which ultimately ranks trials for EPCRS funding support. The EPP trial development and clinical operations are comprised of a Protocol Writer, Contract Specialist, Regulatory Specialists, Clinical Research Specialists, Research Nurses, a Research Program Manager, a dedicated Early Phase Nurse Navigator, and a Pharmacokinetics Technician. The EPP has conducted a wide range of studies that have led to novel scientific discoveries and to the further development of these discoveries in the context of later phase trials supported by NIH grant mechanisms and industry sponsored trials. A large portfolio of novel Early Phase IITs is currently in development and supported by UACC funding. These trials will utilize a broad range of analytic methods, including genomics, proteomics, metabolomics, analytical chemistry, cancer imaging, and bioinformatics.

View original record on NIH RePORTER →